Central Retinal Vein Occlusion Post ChAdOx1 nCoV-19 Vaccination – Can It Be Explained by the Two-hit Hypothesis?

Shweta Parakh

Drishti Eye Institute

Shrey Maheshwari

Drishti Eye Institute

Shrutanjoy Das

Drishti Eye Institute

Hans Vaish

Meher Hospital

Gaurav Luthra

Drishti Eye Institute

Rupesh Agrawal

National Healthcare Group Eye Institute, Tan Tock Seng Hospital

Vishali Gupta

Postgraduate Institute of Medical Education and Research

Saurabh Luthra (✉ drsaurabhluthra@gmail.com)

Drishti Eye Institute

Short Report

Keywords: ChAdOx1 nCoV-19 vaccine, central retinal vein occlusion (CRVO), vaccine-induced immune thrombotic thrombocytopenia (VITT), Anti-PF4 antibodies, SARS-CoV-2, two-hit hypothesis

Posted Date: February 23rd, 2022

DOI: <https://doi.org/10.21203/rs.3.rs-1374901/v1>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

PURPOSE - To report a case of central retinal vein occlusion (CRVO) seven days following the first dose of ChAdOx1 nCoV-19 vaccine.

OBSERVATION - A 31-year-old male presented with CRVO with cystoid macular edema, one week after receiving his first ChAdOx1 nCoV-19 vaccine dose. Apart from mild hyperhomocysteinemia, no major thrombophilic or systemic risk factors were found. Anti-platelet factor 4 antibodies, specific for vaccine-induced immune thrombotic thrombocytopenia, were also negative. However, he tested strongly positive (> 250 U/mL) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) IgG spike antibodies, 2 weeks post the first dose – suggestive of a prior subclinical infection.

CONCLUSION - COVID-19 is known to be associated with an altered host one-carbon metabolism resulting in hyperhomocysteinemia. We hypothesize that a prior subclinical infection with COVID-19 - the first hit - led to hyperhomocysteinemia in our patient and vaccination proved to be the second hit that triggered the thrombotic event. Further studies, including correlation of thrombotic complications with IgG antibody titres post-vaccination, are essential in order to better understand the pathogenesis of such events.

Introduction

Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are the mainstay to fight the coronavirus disease 2019 (COVID-19) pandemic. Eight vaccines have been approved for emergency or full use by at least one regulatory authority recognized by the World Health Organization (WHO) as follows: Pfizer–BioNTech (BNT162b2/COMIRNATY), Oxford–AstraZeneca (AZD1222 Vaxzevria / ChAdOx1-nCoV-19), Sinopharm BIBP (SARS-CoV-2 Vaccine [Vero Cell], Inactivated [InCoV]), Moderna (mRNA 1273), Janssen (Ad26.COV2.S), CoronaVac, Covaxin and Novavax (NVX-CoV2373/Nuvaxovid). Five others are under assessment by the WHO: Sputnik V, Sinopharm WIBP, Convidecia, Sanofi–GSK and SCB-2019.¹

There have been a few reports of central retinal vein occlusion post vaccination against SARS-CoV-2.^{2,3,4,5} We report a case of central retinal vein occlusion (CRVO) in a young male, occurring one week post the first dose of ChAdOx1 nCoV-19 vaccination. He was found to have mild hyperhomocysteinemia and markedly elevated IgG antibody titres against SARS-CoV-2 spike protein. It is now known that SARS-CoV-2 significantly stresses the host's one-carbon metabolism and simultaneously increases demand but reduces supply of methyl-groups.⁶ This biochemical imbalance leads to elevated homocysteine levels, implicated in increased lipid peroxidation, endothelial damage and thromboembolism.^{7,8} The two-hit hypothesis seems to be a reasonable model to explain the course of events in our case. It explains how successive inflammatory or ischemic insults can synergistically lead to an inappropriate immune response, often resulting in organ damage or dysfunction.⁹ We hypothesize that a prior subclinical

infection with COVID-19 led to hyperhomocysteinemia - the first hit - and vaccination proved to be the second hit that finally precipitated the thrombotic complication.

Case

A 31-year-old male presented in February 2021 with complaints of sudden onset, painless diminution of vision in the left eye (OS) for 2 days. Best corrected visual acuity (BCVA) was 6/6 in the right eye (OD) and 6/9 OS. Intraocular pressure was normal in both eyes (OU). Pupils were equal, round and reactive to light OU. Anterior segment examination was unremarkable OU. Dilated fundus examination was within normal limits OD. Fundus and corresponding short-wave fundus autofluorescence (SW-FAF) (Heidelberg Retina Angiograph, Heidelberg Engineering, Heidelberg, Germany) showed markedly dilated tortuous veins, superficial and deep intraretinal hemorrhages in all four quadrants with macular edema, disc hyperemia and few cotton-wool spots OS, suggestive of central retinal vein occlusion (CRVO) (Fig. 1a,b). Spectral-domain optical coherence tomography (SD-OCT) (RTVue XR Avanti, Optovue Inc., Fremont, CA, USA) showed cystoid macular edema (CME) and neurosensory detachment (NSD) with a central macular thickness of 485 microns OS (Fig. 1c). Flow void areas with reduction in vessel density in the superficial capillary plexus was seen in OS on optical coherence tomography angiography (OCTA) (RTVue XR Avanti, Optovue Inc., Fremont, CA, USA) (Fig. 1d,e).

A week before presenting with CRVO, the patient had received his first dose of ChAdOx1 nCoV-19 AstraZeneca vaccine against Coronavirus disease 2019 (COVID-19). He did not have any known medical history of systemic illness including hypertension, diabetes, dyslipidemia, hypercoagulability disorder or autoimmune disease. Blood pressure was normal. Hemogram including platelet count, erythrocyte sedimentation rate and C-reactive protein were normal. HbA1c and lipid profile were within normal limits. Serum homocysteine was mildly elevated at 22.19 micromol/L. A hypercoagulability screening panel, including prothrombin time, activated partial thromboplastin time, serum fibrinogen, D-dimer and anti-phospholipid antibodies (anticardiolipin antibodies, lupus anticoagulant antibodies and anti-beta2-glycoprotein-I antibodies – IgM and IgG), Protein C, Protein S levels were all within normal limits. Real-time reverse transcription–polymerase chain reaction (RT-PCR) for SARS-CoV-2 was negative. Anti-platelet factor 4 (anti-PF4) IgG antibody - specific for vaccine induced thrombotic thrombocytopenia (VITT) - was within normal limits (0.14 U/mL) (biological reference interval <1.00 U/mL). SARS-CoV-2 IgG spike antibody test (SARS-CoV-2 antibodies, nucleocapsid; LabCorp) was strongly positive (> 250 U/mL, biological reference interval < 0.8 negative, > 0.8 positive), 15 days post the first vaccine dose.

Systemic therapy was initiated with oral folic acid, B₆ and B₁₂ vitamin supplementation by the internist. He was administered four intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) ranibizumab (Lucentis®; Genentech, South San Francisco, CA/Roche, Basel, Switzerland) over the next eight months. At the 8-month follow-up visit, BCVA had improved to 6/6 OS. Intraocular pressure was normal OU. Fundus showed reduced intraretinal hemorrhages and cotton-wool spots OS (Fig. 2a,b). Fluorescein angiography (Heidelberg Retina Angiograph, Heidelberg Engineering, Heidelberg, Germany) showed perivascular staining and significant capillary non-perfusion in the temporal periphery OS (Fig.

2c). SD-OCT showed resolution of CME and NSD OS (Fig. 2d). Flow void areas had decreased on OCTA (Fig. 2e,f). Subsequently, he also received two intravitreal anti-VEGF aflibercept (EYLEA; Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA and Bayer Healthcare Pharmaceuticals, Berlin, Germany) for recurrent CME OS. At the latest follow-up, he maintained status quo. All systemic parameters, including serum homocysteine, had normalized and there was no evidence of other systemic thrombotic complications at the end of an eleven-month follow-up.

Discussion

The pathogenetic mechanism of central retinal vein occlusion (CRVO) is based on Virchow's triad of hypercoagulability, endothelial damage and hemostasis - similar to other systemic thrombotic conditions.¹⁰ Elevated prothrombotic markers are a significant risk factor for CRVO in the younger age group. Our patient had no significant predisposing factors except for mildly elevated serum homocysteine (reference intervals - mild 12 to 30 micromol/L, intermediate 31 to 100 micromol/L and severe > 100 micromol/L).^{11,12} In addition, he was found to have markedly elevated IgG antibody titres against SARS-CoV-2 spike protein only 15 days post the first dose. We use the two-hit hypothesis to explain the course of events that led to the vascular occlusion. The two-hit model suggests that an initial inflammation-triggering event can serve as a priming condition for a limited systemic inflammatory response syndrome. Additional hits are capable of causing an exaggerated immune response.¹³

Our patient tested strongly positive (> 250 U/mL) for SARS-CoV-2 IgG spike antibodies, 15 days post the first dose of ChAdOx1 nCoV-19 vaccine. These markedly elevated titres, when temporally correlated with the first dose of the vaccine, suggest that he had possibly been previously infected with COVID-19 prior to vaccination, although he did not show any symptoms. In a recent UK-based study that measured antibody responses in 45,965 adults, who received either the ChAdOx1 or the BNT162b2 SARS-CoV-2 vaccines, it was found that in participants with evidence of prior COVID-19 infection, vaccination increased antibody levels in all age groups.¹⁴ A quantitative analysis of the antibody titres post vaccination revealed the following IgG levels (in ng/ml equivalents, with 95% confidence intervals in parentheses) 28 days post- ChAdOx1 vaccine: 73 (65–81) for 80-year-olds; 94 (87–100) for 60-year-olds; 113 (99–129) for 40-year-olds; and 127 (94–171) for 20-year-olds.¹⁴ These findings are consistent with several previous studies.^{15,16,17} More specifically, the results of a much smaller study on 552 participants in an Indian cohort corroborate with the above studies. It was found that a past history of SARS-CoV-2 infection elicited significantly higher antibody titre compared to SARS-CoV-2 naïve subjects, both after the first (Geometric Mean Titre, GMT, 252.0 vs. 40.8 AU/mL; $p < 0.001$) and second dose (GMT, 302.7 vs. 95.6 AU/mL; $p < 0.001$), irrespective of the type of vaccine received – either ChAdOx1-nCoV (Covishield) and BBV-152 (Covaxin).¹⁸

In order to explain hyperhomocysteinemia post COVID-19 infection, we refer to McCaddon and Regland's article which suggests that SARS-CoV-2 significantly stresses the host's one-carbon metabolism. It simultaneously increases demand but reduces supply of methyl-groups. They proposed that the resultant

biochemical alterations – including serine depletion, elevated homocysteine and glutathione depletion - might explain the varied symptoms of COVID-19 that can persist for weeks or months after symptoms onset.⁶ This condition is called acute post-COVID-19 (from week 5 to week 12), long COVID-19 (from week 12 to week 24), or persistent post-COVID-19 symptoms (lasting >24 weeks).¹⁹ The B12-dependent methionine synthase (MS) reaction is highly pertinent to homocysteine metabolism.⁶ Vitamin B12 is a cofactor of 2 enzymes present in mammalian cells: methionine synthase and methylmalonyl-CoA mutase enzyme. Deficiency of vitamin B12 results in an increase in methylmalonic acid and homocysteine concentration due to inhibition of methylmalonyl-CoA mutase and methionine synthase, respectively.²⁰ Kaur et al.,²¹ proposed that the entry of SARS-CoV-2 facilitated by non-structural protein-14 in the host cell allows the use of cell S-adenosylmethionine for viral RNA capping, resulting in increased homocysteine production and angiotensin-converting enzyme-2 activation, which further augments viral entry into cells.^{22,23} An increased tendency for hypercoagulability and thromboembolism is known to be associated with elevated serum homocysteine.²⁴ Vitamin B12 therapy is known to reduce oxidative damage and improve microvascular disease associated with hyperhomocysteinemia.²⁵ Vitamin B12 is an endogenous negative regulator of nuclear transcription factor- κ B (NF- κ B, nuclear factor kappa-light-chain-enhancer of activated B cells) through the regulation of nitric oxide, which plays a key role in regulating the immune response to infection.^{26,27} More detailed analysis of direct and functional markers of Vitamin B12 (e.g., total B12, holotranscobalamin, total homocysteine and methylmalonic acid, total folic acid) are needed to guide the appropriate form of supplementation, with and without COVID-19 infection.²⁸

ChAdOx1 nCoV-19 vaccines include non-replicating adenoviral vectors, that could induce potent immunological responses due to the presence of viral proteins and stimulation of innate immunity sensors such as toll-like receptors (TLRs).²⁹ Endothelial cells express TLRs, which can precipitate intracellular inflammatory responses via mediators such as NF- κ B that can eventually modulate vascular permeability and coagulation.³⁰ Vaccine adjuvants such as alum, emulsions and TLR agonists, produce characteristic profiles with regard to the type (cellular and/or humoral), duration and strength of immune responses.³¹ Adjuvants, meant to enhance vaccine-mediated immunity, can lead to autoimmune/inflammatory syndrome in a few susceptible or genetically predisposed individuals.³² The response of vascular endothelial cells and their constant contact with immune mediators are vital in understanding the process through which successive insults in a two-hit model can cause tissue injury.³³

In a recent multinational case series of 40 centres, seventy patients were diagnosed with an ocular inflammatory event within 14 days of COVID-19. Most common events reported included anterior uveitis (n = 41, 58.6%), followed by posterior uveitis (n = 9, 12.9%) and scleritis (n = 7, 10.0%). These were mild non-sight threatening events that were based on a temporal association that did not prove causality.³⁴ Commonly proposed mechanisms to explain post-vaccine inflammation include molecular mimicry secondary to similarity between uveal peptides and vaccine peptide fragments apart from antigen-

specific cell and antibody-mediated hypersensitivity reactions. In addition, adjuvants included in the vaccines may stimulate innate immunity through endosomal or cytoplasmic nucleic acid receptors.^{35–39}

Bearing in mind the catastrophic consequences VITT, our patient was investigated and tested negative for anti-PF4 antibodies. VITT, initially known as thrombosis with thrombocytopenia syndrome (TTS), was first reported by Greinacher et al., post ChAdOx1 nCoV-19 vaccination.⁴⁰ This oft-fatal condition presents as extensive thrombosis in atypical sites, most commonly in the cerebral venous sinuses – apart from splanchnic, portal and hepatic veins.⁴¹ It has only recently been proven that anti-PF4 antibodies induced by vaccination do not cross-react with the SARS-CoV-2 spike protein. This illustrates that the expected vaccine-induced immune response against the viral spike protein is not the instigating factor for VITT.⁴²

Conclusion

We report a case of CRVO occurring in close association with and possibly precipitated by ChAdOx1 nCoV-19 vaccination. We hypothesize that a prior subclinical infection with COVID-19 - the first hit - led to hyperhomocysteinemia in our patient and vaccination proved to be the second hit that triggered the thrombotic event. Although CRVO is not a life-threatening thrombotic phenomenon, it is important for ophthalmologists to be aware of a possible causal and temporal association with COVID-19 vaccination, particularly in young patients with no known systemic risk factors or comorbidities. Further research, including correlation of thrombotic complications with IgG antibody titres post-vaccination, are essential in order to better understand the pathogenesis of such events.

Abbreviations

Central retinal vein occlusion (CRVO), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), vaccine-induced immune thrombotic thrombocytopenia (VITT), right eye (OD), left eye (OS), Best corrected visual acuity (BCVA), both eyes (OU), Spectral-domain optical coherence tomography (SD-OCT), cystoid macular edema (CME), neurosensory detachment (NSD), optical coherence tomography angiography (OCTA), Coronavirus disease 2019 (COVID-19), Real-time reverse transcription–polymerase chain reaction (RT-PCR), Anti-platelet factor 4 (anti-PF4), anti-vascular endothelial growth factor (anti-VEGF), nuclear transcription factor-B (NF- κ B, nuclear factor kappa-light-chain-enhancer of activated B cells), toll-like receptors (TLRs), thrombosis with thrombocytopenia syndrome (TTS).

Declarations

Ethics approval and consent to participate: Not applicable.

Consent for publication: The participant provided written consent for publication of this case.

Availability of data and materials: The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests: The authors declare that they have no competing interests.

Fundings: None.

Authors' contributions: All authors contributed to conceptualization and critical review of the brief report. The authors read and approved the final manuscript. The authors are alone responsible for the content of this article.

Acknowledgements: None.

References

1. "Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process". [World Health Organization \(WHO\)](#)
2. Bialasiewicz A, Farah-Diab M, Mebarki H. Central retinal vein occlusion occurring immediately after 2nd dose of mRNA SARS-CoV-2 vaccine. *Int Ophthalmol*. 2021;41(12):3889-3892. doi:10.1007/s10792-021-01971-2
3. Endo B, Bahamon S, Martínez-Pulgarín DF. Central retinal vein occlusion after mRNA SARS-CoV-2 vaccination: A case report. *Indian J Ophthalmol*. 2021;69(10):2865-2866. doi:10.4103/ijo.IJO_1477_21
4. Goyal M, Murthy SI, Srinivas Y. Unilateral retinal vein occlusion in a young, healthy male following Sputnik V vaccination. *Indian J Ophthalmol*. 2021;69(12):3793-3794. doi:10.4103/ijo.IJO_2412_21.
5. Sonawane NJ, Yadav D, Kota AR, Singh HV. Central retinal vein occlusion post-COVID-19 vaccination. *Indian J Ophthalmol*. 2022;70(1):308-309. doi:10.4103/ijo.IJO_1757_21
6. McCaddon A, Regland B. COVID-19: A methyl-group assault?. *Med Hypotheses*. 2021;149:110543. doi:10.1016/j.mehy.2021.110543
7. Bito T, Okumura E, Fujishima M, Watanabe F. Potential of Chlorella as a Dietary Supplement to Promote Human Health. *Nutrients*. 2020;12(9):2524. Published 2020 Aug 20. doi:10.3390/nu12092524
8. Hughes CF, McNulty H. Assessing biomarker status of vitamin B₁₂ in the laboratory: no simple solution. *Ann Clin Biochem*. 2018;55(2):188-189. doi:10.1177/0004563217747907
9. Garrison RN, Spain DA, Wilson MA, Keelen PA, Harris PD. Microvascular changes explain the "two-hit" theory of multiple organ failure. *Ann Surg*. 1998;227(6):851-860. doi:10.1097/00000658-199806000-00008
10. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. *J Thromb Haemost*. 2010;8(9):1886-1894. doi:10.1111/j.1538-7836.2010.03909.x
11. Graham IM, Daly LE, Refsum HM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. *JAMA*. 1997;277(22):1775-1781. doi:10.1001/jama.1997.03540460039030

12. Kang SS, Wong PW, Malinow MR. Hyperhomocyst(e)inemia as a risk factor for occlusive vascular disease. *Annu Rev Nutr.* 1992;12:279-298. doi:10.1146/annurev.nu.12.070192.001431
13. Matsuda N, Hattori Y. Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. *J Pharmacol Sci.* 2006;101(3):189-198. doi:10.1254/jphs.crj06010x
14. Wei J, Stoesser N, Matthews PC, et al. Antibody responses to SARS-CoV-2 vaccines in 45,965 adults from the general population of the United Kingdom. *Nat Microbiol.* 2021;6(9):1140-1149. doi:10.1038/s41564-021-00947-3
15. Krammer F, Srivastava K, Alshammary H, et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med.* 2021;384(14):1372-1374. doi:10.1056/NEJMc2101667
16. Ebinger JE, Fert-Bober J, Printsev I, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. *Nat Med.* 2021;27(6):981-984. doi:10.1038/s41591-021-01325-6
17. Ciccone, E. J. et al. SARS-CoV-2 seropositivity after infection and antibody response to mRNA-based vaccination. Preprint at medRxiv <https://doi.org/10.1101/2021.02.09.21251319> (2021).
18. Singh AK, Phatak SR, Singh R, et al. Antibody response after first and second-dose of ChAdOx1-nCoV (Covishield™®) and BBV-152 (Covaxin™®) among health care workers in India: The final results of cross-sectional coronavirus vaccine-induced antibody titre (COVAT) study. *Vaccine.* 2021;39(44):6492-6509. doi:10.1016/j.vaccine.2021.09.055
19. Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, Cuadrado ML, Florencio LL. Defining Post-COVID Symptoms (Post-Acute COVID, Long COVID, Persistent Post-COVID): An Integrative Classification. *Int J Environ Res Public Health.* 2021;18(5):2621. Published 2021 Mar 5. doi:10.3390/ijerph18052621
20. O'Leary F, Samman S. Vitamin B12 in health and disease. *Nutrients.* 2010;2(3):299-316. doi:10.3390/nu2030299
21. Kaur H, Sarma P, Bhattacharyya A, et al. Folic acid as placebo in controlled clinical trials of hydroxychloroquine prophylaxis in COVID-19: Is it scientifically justifiable?. *Med Hypotheses.* 2021;149:110539. doi:10.1016/j.mehy.2021.110539
22. Li T, Yu B, Liu Z, et al. Homocysteine directly interacts and activates the angiotensin II type I receptor to aggravate vascular injury. *Nat Commun.* 2018;9(1):11. Published 2018 Jan 2. doi:10.1038/s41467-017-02401-7
23. Singh Y, Gupta G, Kazmi I, et al. SARS CoV-2 aggravates cellular metabolism mediated complications in COVID-19 infection. *Dermatol Ther.* 2020;33(6):e13871. doi:10.1111/dth.13871
24. Spence JD. Homocysteine lowering for stroke prevention: Unravelling the complexity of the evidence. *Int J Stroke.* 2016;11(7):744-747. doi:10.1177/1747493016662038
25. Guest J, Bilgin A, Hokin B, Mori TA, Croft KD, Grant R. Novel relationships between B12, folate and markers of inflammation, oxidative stress and NAD(H) levels, systemically and in the CNS of a healthy human cohort. *Nutr Neurosci.* 2015;18(8):355-364. doi:10.1179/1476830515Y.0000000041

26. Manzanares W, Hardy G. Vitamin B12: the forgotten micronutrient for critical care. *Curr Opin Clin Nutr Metab Care*. 2010;13(6):662-668. doi:10.1097/MCO.0b013e32833dfaec
27. Mikkelsen K, Stojanovska L, Prakash M, Apostolopoulos V. The effects of vitamin B on the immune/cytokine network and their involvement in depression. *Maturitas*. 2017;96:58-71. doi:10.1016/j.maturitas.2016.11.012
28. Batista KS, Cintra VM, Lucena PAF, et al. The role of vitamin B12 in viral infections: a comprehensive review of its relationship with the muscle-gut-brain axis and implications for SARS-CoV-2 infection [published online ahead of print, 2021 Nov 13]. *Nutr Rev*. 2021;nuab092. doi:10.1093/nutrit/nuab092
29. Lasaro MO, Ertl HC. New insights on adenovirus as vaccine vectors. *Mol Ther*. 2009;17(8):1333-1339. doi:10.1038/mt.2009.130
30. Khakpour S, Wilhelmsen K, Hellman J. Vascular endothelial cell Toll-like receptor pathways in sepsis. *Innate Immun*. 2015;21(8):827-846. doi:10.1177/1753425915606525
31. Liang Z, Zhu H, Wang X, et al. Adjuvants for Coronavirus Vaccines. *Front Immunol*. 2020;11:589833. Published 2020 Nov 6. doi:10.3389/fimmu.2020.589833
32. Ng XL, Betzler BK, Ng S, et al. The Eye of the Storm: COVID-19 Vaccination and the Eye [published online ahead of print, 2021 Dec 16]. *Ophthalmol Ther*. 2021;1-20. doi:10.1007/s40123-021-00415-5
33. Morris CF, Tahir M, Arshid S, Castro MS, Fontes W. Reconciling the IPC and Two-Hit Models: Dissecting the Underlying Cellular and Molecular Mechanisms of Two Seemingly Opposing Frameworks. *J Immunol Res*. 2015;2015:697193. doi:10.1155/2015/697193
34. Testi I, Brandão-de-Resende C, Agrawal R, Pavesio C; COVID-19 Vaccination Ocular Inflammatory Events Study Group. Ocular inflammatory events following COVID-19 vaccination: a multinational case series. *J Ophthalmic Inflamm Infect*. 2022;12(1):4. Published 2022 Jan 4. doi:10.1186/s12348-021-00275-x
35. Cunningham ET Jr, Moorthy RS, Fraunfelder FW, Zierhut M. Vaccine-Associated Uveitis. *Ocul Immunol Inflamm*. 2019;27(4):517-520. doi:10.1080/09273948.2019.1626188
36. Watad A, De Marco G, Mahajna H, et al. Immune-Mediated Disease Flares or New-Onset Disease in 27 Subjects Following mRNA/DNA SARS-CoV-2 Vaccination. *Vaccines (Basel)*. 2021;9(5):435. Published 2021 Apr 29. doi:10.3390/vaccines9050435
37. Teijaro JR, Farber DL. COVID-19 vaccines: modes of immune activation and future challenges. *Nat Rev Immunol*. 2021;21(4):195-197. doi:10.1038/s41577-021-00526-x
38. Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview. *J Exp Med*. 2016;213(12):2527-2538. doi:10.1084/jem.20161596
39. Cunningham ET Jr, Moorthy RS. Vaccine-Associated Posterior Uveitis. *Retina*. 2020;40(4):595-598. doi:10.1097/IAE.0000000000002816
40. Greinacher A, Thiele T, Warkentin TE, Weisser K, Kyrle PA, Eichinger S. Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination. *N Engl J Med*. 2021;384(22):2092-2101. doi:10.1056/NEJMoa2104840

41. Dotan A, Shoenfeld Y. Perspectives on vaccine induced thrombotic thrombocytopenia. *J Autoimmun.* 2021;121:102663. doi:10.1016/j.jaut.2021.102663
42. Greinacher A, Selleng K, Mayerle J, et al. Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein. *Blood.* 2021;138(14):1269-1277. doi:10.1182/blood.2021012938.

Figures

Figure 1

At the first visit (one week post vaccination)-

(a, b) Multicolor fundus imaging and corresponding short-wave fundus autofluorescence showing disc hyperemia, macular edema, multiple retinal hemorrhages and dilated tortuous veins.

(c) Structural spectral domain optical coherence tomography (SD-OCT) showing cystoid macular edema and neurosensory detachment.

(d) Montage optical coherence tomography angiography (OCTA) image of the optic disc and macula showing flow void areas.

(e) Reduction of vessel density in superficial capillary plexus on OCTA.

Figure 2

At the 8-month follow-up visit. (Post treatment with four intravitreal anti-VEGF ranibizumab injections)

(a, b). Multicolor fundus imaging and corresponding short-wave fundus autofluorescence showing reduced intraretinal hemorrhages, cotton-wool spots and venous tortuosity.

- (c) Fluorescein angiography showing late perivascular staining and capillary non-perfusion in the temporal periphery.
- (d) Structural spectral domain optical coherence tomography showing resolution of cystoid macular edema and neurosensory detachment.
- (e) Montage optical coherence tomography angiography (OCTA) of the optic disc and macula showing reduction in flow void areas.
- (f) Recovery of vessel density in superficial capillary plexus on OCTA.